Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Insulin glargine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Semglee with alcohol
Semglee contains insulin glargine. This is a modified insulin, very similar to human insulin.
Your blood sugar levels may either rise or fall if you drink alcohol.
Semglee is used to treat diabetes mellitus in adults,
Pregnancy and breast-feeding
This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). Do not stop Semglee without speaking to a doctor, who will tell you what needs to be done.
Ask your doctor or pharmacist for advice before taking any medicine.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
produce enough insulin to control the level of blood sugar. Insulin glargine has a long and steady blood-sugar-lowering action.
e Semglee Do not use Semglee
Semglee in pre-filled pen is only suitable for injecting just under the skin (See also section 3). Speak to your doctor if you need to inject your insulin by another method.
Talk to your doctor, pharmacist or nurse before using Semglee. Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical activity (physical work and exercise), injection technique as discussed with your doctor. Skin changes at the injection site: The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work
very well if you inject into a lumpy area (see How to use Semglee). Contact your doctor if you are currently injecting into a lumpy area before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose. If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet). Travel Before travelling consult your doctor. You may need to talk about
feel unwell or become ill. Illnesses and injuries In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):
Inform your doctor if you are planning to become pregnant,
or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after giving birth. Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby. If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet. Driving and using machines
Your ability to concentrate or react may be reduced if:
advice on driving if:
Semglee contains sodium This medicine contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially 'sodium-free'.
Check with your doctor or pharmacist if you are not sure.
Although Semglee contains the same active substance as insulin glargine 300 units/ml, these medicines are not interchangeable. The switch from one insulin therapy to another requires medical prescription, medical supervision
localised swelling (oedema). Children There is no experience with the use of Semglee in children below the age of 2 years. Other medicines and Semglee
Semglee can be used in adolescents and children aged 2 years and above. Use this medicine exactly as your doctor has told you. You need one injection of Semglee every day, at the same time of the day. Semglee pen delivers insulin in increments of 1 unit up toa
maximum single dose of 80 units. Method of administration Semglee is injected under the skin, Do NOT inject Semglee in a vein, since this will change its action and may cause hypoglycaemia. Your doctor will show you in which area of the skin you should inject Semglee. With each injection, change the puncture site within the particular area of skin that you are
using. How to handle Semglee pen Semglee in pre-filled pen is only suitable for injecting just
Some medicines cause changes in the blood sugar level (decrease, increase or both depending on the situation). In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are either too low or too high. Be careful when you start or stop taking another medicine.
these Instructions for Use,
Tell your doctor or pharmacist if you are taking, have
A new needle must be attached before each use. Only
recently taken or might take any other medicines. Before
under the skin. Speak to your doctor if you need to inject your insulin by another method. Read carefully the "Instructions for Use" included in this package leaflet. You must use the pen as described in
use needles that are compatible with Semglee pen (see
taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.
"Instructions for Use"), A safety test must be performed before each injection.
Medicines that may cause your blood sugar level to fall
Look at the cartridge before you use the pen. Do not use Semglee if you notice particles in the solution. Only use Semglee if the solution is clear and colourless, Do not shake or mix it before use.
(hypoglycaemia) include:
–
disopyramide (used to treat certain heart conditions), fluoxetine (used to treat depression), fibrates (used to lower high levels of blood lipids), monoamine oxidase (MAO) inhibitors (used to treat depression),
99 |Gwas
[w/s}un QOL
Your blood sugar level may either rise or fall if you take:
swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heart beat and sweating. Severe allergic reactions to insulins may become life-threatening. Tell a doctor straight away if you notice signs of severe allergic reaction.
100 people) or thicken (lipohypertrophy; may affect up to 1 in 10 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes.
¢ Skin and allergic reactions at the injection site
to insulins usually disappear in a few days to a few weeks. Rare reported side effect (may affect up to 1 in 1,000 people) ¢ Eye reactions A marked change (improvement or worsening) in your blood sugar control can disturb your vision temporarily. If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision. ¢ General disorders In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles. Very rare reported side effects (may affect up to 1 in 10,000 people) In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur. Use in children and adolescents In general, the side effects in children and adolescents of
18 years of age or less are similar to those seen in adults. Complaints of injection site reactions (injection site reaction, injection site pain) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults. There is no experience in children under 2 years.
Always carry some sugar (at least 20 grams) with you. Carry some information with you to show you are
diabetic. HYPERGLYCAEMIA (high blood sugar levels) If your blood sugar is too high (hyperglycaemia), you may not have injected enough insulin.
Why does hyperglycaemia occur? Examples include:
incorrect storage,
reddening of the face, loss of appetite, low blood pressure, fast heart beat, and glucose and ketone bodies in urine.
Stomach pain, fast and deep breathing, sleepiness or even loss of consciousness may be signs of a serious condition (ketoacidosis) resulting from lack of insulin. What should you do if you experience hyperglycaemia? Test your blood sugar level and your urine for ketones as soon as any of the above symptoms occur. Severe hyperglycaemia or ketoacidosis must
always be treated by a doctor, normally in a hospital.
HYPOGLYCAEMIA (low
blood sugar levels)
If your blood sugar level falls too much you may become unconscious. Serious hypoglycaemia may cause a heart attack or brain damage and may be life-threatening. You
normally should be able to recognise when your blood sugar is falling too much so that you can take the right
actions. Why does hypoglycaemia occur?
Examples include:
sweeteners are NOT carbohydrates),
stress,
Semglee"). Hypoglycaemia is also more likely to occur if
of hypoglycaemia
blood pressure, palpitations and irregular heartbeat. These symptoms often develop before the symptoms of a low sugar level in the brain.
Reporting of side effects
the brain: headaches, intense hunger, nausea, vomiting,
If you get any side effects, talk to your doctor or
tiredness, sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in concentration, impaired
pharmacist. This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via United Kingdom
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard Or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Semglee
DO9 C6X8
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: United Kingdom (Northern Ireland) Biosimilars Newco Limited Tel: 0080008250910
Do not take a double dose to make up for a forgotten dose.
Diabetes mellitus is a disease where your body does not
Dublin
insulins.
If you are not sure whether you are taking one of those
as clonidine, guanethidine, and reserpine) may weaken or suppress entirely the first warning symptoms which help
Block B, The Crescent Building, Santry Demesne
Ireland
you to recognise a hypoglycaemia.
Beta-blockers like other sympatholytic medicines (such
D13 R20R
You must always check the insulin label before each injection to avoid mix-ups between Semglee and other
If you have missed a dose of Semglee or if you have not injected enough insulin, your blood sugar level may become too high (hyperglycaemia). Check your blood sugar frequently. For information on the treatment of hyperglycaemia, see box at the end of this leaflet.
adolescents and children aged 2 years and above.
woqoaup Bupeas 'poseuieud
To prevent the possible transmission of disease, never share your pen with anyone else. This pen is only for your use.
Semglee 100 units/ml solution for injection in a pre-filled pen is a clear colourless solution.
Each pen contains 3 ml of solution for injection (equivalent to 300 units). Semglee is available in pack sizes of 1, 3, 5, 10 pens and in a multipack compromising of 2 cartons, each containing 5 pens.
Not all pack sizes may be marketed.
It is advisable to test your blood sugar immediately after taking glucose to check that you really have hypoglycaemia.
gS Biocon Biologics
5. How to store Semglee 6. Contents of the pack and other information
Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia.
Marketing Authorisation Holder Biosimilar Collaborations Ireland Limited
Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. If you think you may have a problem with Semglee pen, consult your doctor, pharmacist or nurse.
Unit 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13 DUBLIN
Empty pens must not be re-filled and must be properly discarded.
Ireland
Do not use Semglee pen if it is damaged or not working properly (due to mechanical defects), it has to be discarded and a new Semglee pen has to be used.
Manufacturer Biosimilar Collaborations Ireland Limited
Insulin mix-ups
If you use more Semglee than you should If you have injected too much Semglee, your blood sugar level may become too low (hypoglycaemia). Check your blood sugar frequently. In general, to prevent hypoglycaemia you must eat more food and monitor
your blood sugar. For information on the treatment of hypoglycaemia, see box at the end of this leaflet. If you forget to use Semglee
medicines ask your doctor or pharmacist.
If you stop using Semglee
Semglee Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the label of the pen after "EXP", The expiry date refers to the last day of that month. Not in-use pens Store in a refrigerator (2°C-8°C). Do not freeze or place next
reactions, depression, confusion, speech disturbances
(sometimes total loss of speech), visual disorders, trembling, paralysis, tingling sensations (paraesthesia), numbness and tingling sensations in the area of the mouth, dizziness, loss of self-control, inability to look after yourself, convulsions, loss of consciousness. The first symptoms which alert you to hypoglycaemia ("warning symptoms") may change, be weaker or may be
missing altogether if
(diabetic autonomic neuropathy),
to the freezer compartment of your refrigerator or a freezer pack. Keep the pre-filled pen in the outer carton in order to
(see section 2, "Other medicines and Semglee"). In such a case, you may develop severe hypoglycaemia (and even faint) before you are aware of the problem.
protect from light.
Be familiar with your warning symptoms. If necessary, more frequent blood sugar testing can help to identify mild hypoglycaemic episodes that may otherwise be
In-use pens Pre-filled pens in use or carried as a spare may be stored for a maximum of 4 weeks not above 25°C and away from direct heat or direct light. Do not use it after this time
overlooked. If you are not confident about recognising your warning symptoms, avoid situations (such as driving a car) in which you or others would be put at risk by
hypoglycaemia.
injection in order to protect from light.
What should you do if you experience hypoglycaemia?
Remove the needle after the injection and store the pen without the needle. Also, be sure to remove the needle
1. Do not inject insulin. Immediately take about 10 to 20 g sugar, such as glucose, sugar cubes or a sugar-sweetened beverage. Caution: Artificial sweeteners and foods with artificial sweeteners (such as diet drinks) are of no help in treating hypoglycaemia. 2. Then eat something that has a long-acting effect in raising your blood sugar (such as bread or pasta). Your doctor or nurse should have discussed this with you previously. The recovery of hypoglycaemia may be delayed because Semglee has a long action. 3. If the hypoglycaemia comes back again take another 10 to 20 g sugar. 4, Speak to a doctor immediately if you are not able to control the hypoglycaemia or if it recurs. Tell your relatives, friends and close colleagues the following: If you are not able to swallow or if you are unconscious, you will require an injection of glucose or glucagon (a medicine which increases blood sugar). These injections are justified even if it is not certain that you have hypoglycaemia.
before disposing of the pen. Needles must not be re-used, Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Zanes 99 |Gwas ®
reactions (rash and itching all over the body), severe
What Semglee contains
Severe allergic reactions (rare, may affect up to 1 in 1,000 people) – the signs may include large-scale skin
10/66900448
phenothiazine derivatives (used to treat psychiatric disorders),
end of this leaflet.
®
–
falls too low you may pass out (become unconscious). Serious hypoglycaemia may cause brain damage and may be life-threatening. For more information, see the box at the
period. The pen in use must not be stored in a refrigerator. The pen cap must be put back on the pen after each
Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:
hypoglycaemia),
level straight away (see the box at the end of this leaflet). Hypoglycaemia (low blood sugar) can be very serious and is very common with insulin treatment (may affect more than 1 in 10 people). Low blood sugar means that there is not enough sugar in your blood. If your blood sugar level
when injecting, itching, hives, swelling or inflammation. This can spread around the injection site. Most minor reactions
Frequency of administration
as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or
(hypoglycaemia), take action to increase your blood sugar
Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will
Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin). However, only very rarely, this will require a change to your insulin dose.
with pioglitazone (oral anti-diabetic medicine used to treat type 2 diabetes mellitus) and insulin experienced the development of heart failure. Inform your doctor as soon
If you notice signs of your blood sugar being too low
The signs may include reddening, unusually intense pain
Many factors may influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. See the box at the end of this leaflet for further information.
HYPOGLYCAEMIA
Thirst, increased need to urinate, tiredness, dry skin,
Dose
Semglee is a long-acting insulin. Your doctor may tell you to use it in combination with a short-acting insulin or with tablets used to treat high blood sugar levels.
AND
Warning symptoms of hyperglycaemia
Common reported side effects (may affect up to 1 in 10 people)
HYPERGLYCAEMIA
Like all medicines, this medicine can cause side effects,
and blood glucose monitoring. Please, consult your doctor for further information,
at what time,
This leaflet was last revised in June 2024
although not everybody gets them.
tissue may either shrink (lipoatrophy; may affect up to 1 in
Always use this medicine exactly as your doctor has told you.
Use in children and adolescents
and heart disease or previous stroke who were treated
elo)
If you inject insulin too often at the same place, the fatty
If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates. Always tell people who are caring for you or treating you that you require insulin.
Some patients with long-standing type 2 diabetes mellitus
Ce ool
Skin changes at the injection site
Semglee 100 units/ml solution for injection in pre-filled pen comes as injection containing 100iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Semglee 100 units/ml solution for injection in pre-filled pen is insulin glargine.
Medicines with the same active substance, strength and form include: ABASAGLAR 100 units/mL KwikPen solution for injection in a pre-filled pen, ABASAGLAR 100 units/mL Tempo Pen solution for injection in a pre-filled pen, ABASAGLAR 100 units/mL solution for injection in a cartridge. In total there are 6 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Semglee 100 units/ml solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
Posology
Semglee contains insulin glargine, an insulin analogue, and has a prolonged duration of action.
It should be administered once daily at any time but at the same time each day.
The pre-filled pen delivers insulin in increments of 1 unit up to a maximum single dose of 80 units.
The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, Semglee can also be given together with orally active antidiabetic medicinal products.
The potency of this medicinal product is stated in units. These units are exclusive to Semglee and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1).
Special population
Elderly population (≥ 65 years old)
In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.
Renal impairment
In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Hepatic impairment
In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Paediatric population
• Adolescents and children aged 2 years and older patients
Safety and efficacy of Semglee have been established in adolescents and children aged 2 years and older (see section 5.1). The dose regimen (dose and timing) should be individually adjusted.
• Children below 2 years of age
The safety and efficacy of Semglee have not been established. No data are available.
Switch from other insulins to Semglee
When switching from a treatment regimen with an intermediate or long-acting insulin to a regimen with Semglee, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products).
Switch from twice daily NPH insulin to Semglee
To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with Semglee should reduce their daily dose of basal insulin by 20-30% during the first weeks of treatment.
Switch from insulin glargine 300 units/ml to Semglee
Semglee and insulin glargine 300 units/ml are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily insulin glargine 300 units/ml to a once daily regimen with Semglee should reduce their dose by approximately 20%.
During the first weeks the reduction should, at least partially, be compensated by an increase in mealtime insulin, after this period the regimen should be adjusted individually.
Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.
With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary. Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypo- or hyperglycaemia (see section 4.4).
Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Semglee.
Method of administration
Semglee is administered subcutaneously.
Semglee should not be administered intravenously. The prolonged duration of action of Semglee is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.
There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of Semglee. Injection sites must be rotated within a given injection area from one injection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).
Semglee must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.
Semglee in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe is necessary, a vial should be used (see section 4.4).
Before using the pre-filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6).
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.
Warnings
Semglee is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long-acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.
Hypoglycaemia
The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed. Due to more sustained basal insulin supply with Semglee, less nocturnal but more early morning hypoglycaemia can be expected.
Particular caution should be exercised, and intensified blood glucose monitoring is advisable in patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient amaurosis following hypoglycaemia).
Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or be absent in certain risk groups. These include patients:
- in whom glycaemic control is markedly improved,
- in whom hypoglycaemia develops gradually,
- who are elderly,
- after transfer from animal insulin to human insulin,
- in whom an autonomic neuropathy is present,
- with a long history of diabetes,
- suffering from a psychiatric illness,
- receiving concurrent treatment with certain other medicinal products (see section 4.5).
Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient's awareness of hypoglycaemia.
The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia.
If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent, unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered.
Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment. These include:
- change in the injection area. Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered,
- improved insulin sensitivity (e.g., by removal of stress factors),
- unaccustomed, increased or prolonged physical activity,
- intercurrent illness (e.g. vomiting, diarrhoea),
- inadequate food intake,
- missed meals,
- alcohol consumption,
- certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency),
- concomitant treatment with certain other medicinal products (see section 4.5).
Intercurrent illness
Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely.
Insulin antibodies
Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 5.1).
Handling of the pen
Semglee in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe is necessary, a vial should be used (see section 4.2).
Before using Semglee pen, the instructions for use included in the package leaflet must be read carefully.
Semglee pen has to be used as recommended in these instructions for use (see section 6.6).
Medication errors
Medication errors have been reported in which other insulins, particularly short-acting insulins, have been accidentally administered instead of insulin glargine. Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins.
Combination of Semglee with pioglitazone
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Semglee is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema.
Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Excipients
This medicinal product contains less than 1 mmol (23 mg) sodium per dose, i.e. it is essentially 'sodium-free'.
A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent.
Pregnancy
For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not indicate reproductive toxicity.
The use of Semglee may be considered during pregnancy, if clinically needed.
It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential.
Breast-feeding
It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breast-fed newborn/infant are anticipated since insulin glargine as a peptide is digested into aminoacids in the human gastrointestinal tract. Breast-feeding women may require adjustments in insulin dose and diet.
Fertility
Animal studies do not indicate direct harmful effects with respect to fertility.
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or use machines in these circumstances.
Summary of the safety profile
Hypoglycaemia (very common), in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement (see section 4.4).
Tabulated list of adverse reactions
The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000; not known: cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
MedDRA system organ classes
Very common
Common
Uncommon
Rare
Very rare
Not known
Immune system disorders
Allergic reactions
Metabolism and nutrition disorders
Hypoglycaemia
Nervous system disorders
Dysgeusia
Eyes disorders
Visual impairment
Retinopathy
Skin and subcutaneous tissue disorders
Lipohypertrophy
Lipoatrophy
Cutaneous amyloidosis
Musculoskeletal and connective tissue disorders
Myalgia
General disorders and administration site conditions
Injection site reactions
Oedema
Description of selected adverse reactions
Metabolism and nutrition disorders
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening.
In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms (see section 4.4).
Immune system disorders
Immediate-type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening.
Eyes disorders
A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. In patients with proliferative retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.
Skin and subcutaneous tissue disorders
Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).
General disorders and administration site conditions
Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.
Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.
Paediatric population
In general, the safety profile for children and adolescents (≤ 18 years of age) is similar to the safety profile for adults.
The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (≤ 18 years of age) than in adults.
Clinical study safety data are not available for children under 2 years.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard
Or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia.
Management
Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates.
Adjustments in dose of the medicinal product, meal patterns, or physical activity may be needed.
More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose.
Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.
Ask anything about Semglee 100 units/ml solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.